Servier shared that sevasemten did not meet the primary endpoint in the Phase 3 trial in Becker muscular dystrophy

Becker muscular dystrophy

Servier announced that topline results from the 18-month placebo controlled GRAND CANYON study in Becker muscular dystrophy did not meet the primary endpoint, with no statistically significant benefit on the North Star Ambulatory Assessment over 18 months.  Secondary endpoints were also not met. 

We recognize this is disappointing news, and that many in our community may have questions.  We will share more information as it becomes available from the company. 

Link to press release HERE